HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Giulio Rizzoli Gaetano Thiene Dino Casarotto Gino Gerosa Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bottio, T. Articles by Gerosa, G. Search for Related Content PubMed PubMed Citation Articles by Bottio, T. Articles by Gerosa, G. Related Collections Valve disease

J Thorac Cardiovasc Surg 2004;127:1616-1623
© 2004 The American Association for Thoracic Surgery

Surgery for acquired cardiovascular disease

Hemodynamic and clinical outcomes with the Biocor valve in the aortic position: An 8-year experience

^a Department of Cardiovascular Surgery, University of Padua Medical School, Padua, Italy,
^b Department of Pathology, University of Padua Medical School, Padua, Italy

Received for publication July 9, 2003; revisions received August 29, 2003; accepted for publication October 3, 2003.

^* Address for reprints: Tomaso Bottio, MD, Department of Cardiovascular Surgery, Via Giustiniani, 2, 35128, Padova, Italy
tomaso.bottio{at}unipd.it

OBJECTIVES: The aim of this study was to analyze the 8-year experience, survival, prosthetic complications, and hemodynamics of patients who received the Biocor valve, a new-generation tissue valve, in the aortic position.

METHODS: From May 1992 through May 2001, 257 consecutive patients (129 women and 128 men; mean age, 75 ± 6 years; age range, 45-91 years) received 258 aortic Biocor porcine prostheses. One female patient who received 2 Biocor valves in the aortic position during 2 consecutive operations was entered twice in the statistical analysis. Twelve (4.6%) patients had previous aortic valve operations. Preoperatively, 82 (32%) patients were in New York Heart Association functional class III or IV. Associated surgical procedures included coronary artery bypass grafting in 56 (21.7%) patients, aortic annular enlargement or aortoplasty in 20 (8%) patients, and others in 8 (3%) patients. Echocardiography was performed in the majority of long-term survivors (91.6%). Follow-up included 1215 patient-years and was 100% complete, with a median time of 5 patient-years (range, 0.4-10.5 years).

RESULTS: There were 16 (6.2%) early deaths. According to a univariate analysis, New York Heart Association functional class III or IV, concomitant procedures, ejection fractions of less than 40%, and urgent operations were identified as significant perioperative risk factors. At follow-up, 75 patients died; 8-year actuarial Kaplan-Meier survival was 48% ± 5%. At 8 years, the actuarial freedom from valve-related death was 92% ± 2.6%, the freedom from thromboembolism was 93% ± 2%, the freedom from anticoagulant-related hemorrhage was 95% ± 2%, the freedom from endocarditis was 99% ± 0.6%, the freedom from paravalvular leak was 96% ± 1.5%, the freedom from all valve-related complications was 78% ± 4.5%, and the freedom from structural valve deterioration was 95% ± 3.7%. At 8 years, the actuarial freedom from structural valve deterioration was 89% ± 10% and 95.8% ± 4% in patients younger and older than 65 years, respectively. At 10 years, in patients older than 65 years, the actual freedom from structural valve deterioration was 97.9% ± 2.1%, and the freedom from reoperation was 97% ± 1.3%. New York Heart Association status was I or II in 90% of patients at the end of follow-up. The mean echocardiographic follow-up time was 4.6 ± 2 years. By using Doppler echocardiography, the peak and mean transprosthetic gradients were determined to be 30.8 ± 9.3 mm Hg and 16.6 ± 5.3 mm Hg, respectively. Mean mass/volume ratio and left ventricular end-diastolic volume were 1.37 ± 0.17 g/mL and 63.4 ± 22.6 mL/m², respectively. The majority of patients showed a persistent left ventricular hypertrophy.

CONCLUSION: The Biocor is an effective bioprosthesis with a low incidence of valve-related complications comparable with that of other second-generation bioprostheses. This stented porcine prosthesis provides satisfactory results in terms of hemodynamics, valve durability, and freedom from reoperation.

This article has been cited by other articles:

				W. B. Eichinger, I. M. Hettich, D. J. Ruzicka, K. Holper, C. Schricker, S. Bleiziffer, and R. Lange Twenty-year experience with the st. Jude medical biocor bioprosthesis in the aortic position. Ann. Thorac. Surg., October 1, 2008; 86(4): 1204 - 1210. [Abstract] [Full Text] [PDF]

				T. Bottio, M. Valente, G. Rizzoli, V. Tarzia, G. Bisleri, E. Pettenazzo, G. Gerosa, and G. Thiene Commissural dehiscence: a rare and peculiar cause of porcine valve structural deterioration. J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1017 - 1022. [Abstract] [Full Text] [PDF]